Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation

European Journal of Cancer

Volumn 43, Issue 10, 2007, Pages 1502-1507

  Hambek, Markus ^a   Werner, Christian ^a   Baghi, Mehran ^a   Gstöttner, Wolfgang ^a   Knecht, Rainald ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Chemotherapy; Docetaxel; G0 cells; SCCHN

Indexed keywords

CYTOKINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; KI 67 ANTIGEN; SEROTONIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL STIMULATION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; DRUG SYNERGISM; G0 PHASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; KI-67 ANTIGEN; SEROTONIN; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 34250156675     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.09.037     Document Type: Article

References (43)

1. Devriendt D., and Klastersky J. New cytostatic agents for the treatment of head and neck cancer. Acta Otorhinolaryngol Belg 51 2 (1997) 61-68
2. Schoffski P., Weihkopf T., and Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. Anticancer Res 18 6B (1998) 4751-4756
3. Janinis J., et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 23 2 (2000) 128-131
4. Janinis J., et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24 3 (2001) 227-231
5. Posner M.R., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 4 (2001) 1096-1104
6. Colevas A.D., et al. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol 25 2 (2002) 153-159
7. Tishler R.B., et al. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 95 7 (2002) 1472-1481
8. Haddad R., et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97 2 (2003) 412-418
9. Haddad R., et al. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8 1 (2003) 35-44
10. Posner M.R., and Lefebvre J.L. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 88 1 (2003) 11-17
11. Watanabe A., Taniguchi M., and Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 14 10 (2003) 801-807
12. Ghi M.G., et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys 59 2 (2004) 481-487
13. Katori H., et al. Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Br J Cancer 90 2 (2004) 348-352
14. Shibuya Y., et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer. Kobe J Med Sci 50 1-2 (2004) 1-7
15. Tsukuda M., et al. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck. Int J Clin Oncol 9 3 (2004) 161-166
16. Katori H., et al. [Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)]. Nippon Jibiinkoka Gakkai Kaiho 108 2 (2005) 157-163
17. Knecht R., et al. EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment. Adv Otorhinolaryngol 62 (2005) 81-91
18. Fu K.K., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 1 (2000) 7-16
19. Hitt R., et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41 3 (2005) 453-460
20. Rubin Grandis J., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 11 (1998) 824-832
21. Grandis J.R., et al. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69 1 (1998) 55-62
22. Maurizi M., et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74 8 (1996) 1253-1257
23. Jedema I., et al. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Exp Hematol 32 2 (2004) 188-194
24. Jedema I., et al. Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia 17 10 (2003) 2049-2051
25. Banes A.K., et al. Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol 288 4 (2005) C805-C812
26. To K.F., et al. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 91 7 (2004) 1335-1341
27. Song L., et al. IL-6 inhibits apoptosis of human myeloma cell line XG-7 through activation of JAK/STAT pathway and up-regulation of Mcl-1. Ai Zheng 21 2 (2002) 113-116
28. McLemore M.L., et al. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. Immunity 14 2 (2001) 193-204
29. Berclaz G., et al. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol 19 6 (2001) 1155-1160
30. Da Silva N., et al. G-CSF activates STAT pathways in Kasumi-1 myeloid leukemic cells with the t(8; 21) translocation: basis for potential therapeutic efficacy. Cytokines Cell Mol Ther 3 2 (1997) 75-80
31. Shah J.P., et al. Carcinoma of the hypopharynx. Am J Surg 132 4 (1976) 439-443
32. Wang S.W., et al. YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 312 3 (2005) 917-925
33. Hashimoto T., et al. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64 9 (2004) 3344-3349
34. Polek T.C., et al. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144 1 (2003) 50-60
35. Liu J.D., et al. Molecular mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Mol Carcinog 37 1 (2003) 39-50
36. Denkert C., et al. Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene 22 54 (2003) 8653-8661
37. Clark S.S., et al. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. Leukemia 16 2 (2002) 213-222
38. Russo P., et al. RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. Int J Oncol 18 4 (2001) 855-862
39. Kuroki J., et al. Cell-permeable ceramide inhibits the growth of B lymphoma Raji cells lacking TNF-alpha-receptors by inducing G0/G1 arrest but not apoptosis: a new model for dissecting cell-cycle arrest and apoptosis. Leukemia 10 12 (1996) 1950-1958
40. Mullen P., Scott W.N., and Miller W.R. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 63 6 (1991) 930-932
41. Sutherland R.L., et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 19 5 (1983) 615-621
42. Kamikubo K.H., et al. Low proportion of G0-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia. Int J Hematol 71 3 (2000) 249-255
43. Bolton W.E., et al. Expression of proliferation-associated antigens (PCNA, p120, p145) during the reentry of G0 cells into the cell cycle. Cytometry 17 1 (1994) 66-74